Menopausal Hormone Therapy And Left Ventricular Function
1 other identifier
observational
50
1 country
1
Brief Summary
The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 17, 2025
CompletedFirst Posted
Study publicly available on registry
November 21, 2025
CompletedStudy Start
First participant enrolled
July 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
Study Completion
Last participant's last visit for all outcomes
December 1, 2027
April 23, 2026
April 1, 2026
1.4 years
November 17, 2025
April 22, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Left ventricular stroke volume
Left ventricular stroke volume is the amount of blood pumped from the left ventricle per heartbeat (mL)
Baseline
Secondary Outcomes (1)
Ventriculo-Arterial (VA) coupling
Baseline
Study Arms (2)
Post-menopausal females using menopausal hormone therapy
Post menopausal females taking a clinically prescribed menopausal hormone therapy (i.e. pill, patch, etc.)
Post-menopausal females not using menopausal hormone therapy
Interventions
Taken in accordance with standard clinical practice, administered for a minimum duration of eight weeks.
Eligibility Criteria
Study participants will be recruited from various Mayo Clinic departments/clinics located at Rochester and surrounding communities.
You may qualify if:
- \>45-60\< years of age
You may not qualify if:
- Male sex
- Females between STRAW+10 stages -5 and 0
- PMF in STRAW+10 stage +2
- PMF using oral hormone therapy
- Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
- Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
- Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
- Pregnancy
- COPD
- Diabetes
- CKD
- Raynaud's phenomenon
- Sleep disorders
- Shift workers
- BMI ≥40.0kg/m2
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joshua Bock, Ph.D.
Mayo Clinic
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 17, 2025
First Posted
November 21, 2025
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
April 23, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share